We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OKUR
76
OnKure Therapeutics
OKUR
$154M
$2.18M 0.3%
253,754
+151,187
+147% +$2.29M
GLUE icon
77
Monte Rosa Therapeutics
GLUE
$1.4B
$2.16M 0.29%
311,575
-18
-0% -$135
SLRN
78
DELISTED
ACELYRIN
SLRN
$2.12M 0.29%
676,608
-466
-0.1% -$2.26K
RCUS icon
79
CALL
Arcus Biosciences
RCUS
$3.55B
$2.1M 0.29%
141,000
+27,300
+24% +$446K
HROW icon
80
CALL
Harrow
HROW
$1.45B
$1.96M 0.27%
+58,300
New +$2.58M
CRDF icon
81
Cardiff Oncology
CRDF
$66.5M
$1.95M 0.27%
+450,000
New +$1.41M
SGMO
82
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.9M 0.26%
+1,860,179
New +$3.4M
NKTR icon
83
Nektar Therapeutics
NKTR
$2.39B
$1.89M 0.26%
135,269
+47,775
+55% +$843K
TARA icon
84
Protara Therapeutics
TARA
$220M
$1.85M 0.25%
350,489
+194,777
+125% +$629K
ALEC icon
85
Alector
ALEC
$168M
$1.8M 0.24%
+950,000
New +$3.58M
TERN
86
DELISTED
Terns Pharmaceuticals
TERN
$1.71M 0.23%
308,491
-6
-0% -$41
BMEA icon
87
PUT
Biomea Fusion
BMEA
$84.6M
$1.67M 0.23%
431,100
+378,100
+713% +$3.01M
ACHL
88
DELISTED
Achilles Therapeutics
ACHL
$1.64M 0.22%
1,441,141
-2,040
-0.1% -$2.1K
IMUX icon
89
Immunic
IMUX
$190M
$1.61M 0.22%
161,417
+112,067
+227% +$1.41M
GALT icon
90
CALL
Galectin Therapeutics
GALT
$196M
$1.55M 0.21%
1,200,000
+700,000
+140% +$1.68M
GALT icon
91
PUT
Galectin Therapeutics
GALT
$196M
$1.55M 0.21%
1,200,000
+700,000
+140% +$1.68M
ANRO icon
92
Alto Neuroscience
ANRO
$1.05B
$1.48M 0.2%
+350,000
New +$2.18M
IBIO icon
93
iBio
IBIO
$69.5M
$1.47M 0.2%
599,913
-87
-0% -$224
CDTX
94
DELISTED
Cidara Therapeutics
CDTX
$1.45M 0.2%
+53,940
New +$876K
TRML
95
DELISTED
Tourmaline Bio
TRML
$1.38M 0.19%
67,927
-40,556
-37% -$1.02M
SWTX
96
DELISTED
SpringWorks Therapeutics
SWTX
$1.36M 0.18%
+37,519
New +$1.31M
TRVI icon
97
Trevi Therapeutics
TRVI
$2.59B
$1.34M 0.18%
+325,000
New +$1.04M
DCTH icon
98
Delcath Systems
DCTH
$422M
$1.21M 0.16%
100,365
-5
-0% -$53
SLDB icon
99
CALL
Solid Biosciences
SLDB
$794M
$1.2M 0.16%
300,000
– –
ALT icon
100
CALL
Altimmune
ALT
$552M
$1.19M 0.16%
+165,700
New +$1.27M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.